Lenvima (lenvatinib) — Medica

Endometrial carcinoma

Initial criteria

age ≥ 18 years
Patient meets ONE of the following (i or ii):
i. Patient meets ALL of the following (a, b, and c): patient has advanced endometrial carcinoma that is mismatch repair proficient (pMMR); AND medication is used in combination with Keytruda (pembrolizumab intravenous injection); AND patient has tried at least one systemic therapy (e.g., carboplatin, paclitaxel, docetaxel, cisplatin, doxorubicin, or ifosfamide); OR
ii. Lenvima is used as a single agent for second-line or subsequent therapy
Patient is not a candidate for curative surgery or radiation

1 year